These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37690873)

  • 41. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
    Shoukat A; Bawden CE; Röst G; LeBlanc JJ; Galvani AP; Langley JM; Moghadas SM
    Vaccine; 2024 Mar; 42(7):1768-1776. PubMed ID: 38368226
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Health care costs of hospitalization of young children for respiratory syncytial virus infections: a population-based matched cohort study.
    Thampi N; Knight BD; Thavorn K; Webster RJ; Lanctot K; Hawken S; McNally JD
    CMAJ Open; 2021; 9(4):E948-E956. PubMed ID: 34667075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
    Munoz FM
    Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C; Kauf TL; Saidi AS; Winterstein AG
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prevention of respiratory syncytial virus infection in infants. What has been done and where are we today?].
    Novoa Pizarro JM; Lindemann Tappert BC; Luchsinger Farías VR; Vargas Munita SL
    Andes Pediatr; 2023 Dec; 94(6):672-680. PubMed ID: 38329302
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022.
    Fitzpatrick MC; Laufer RS; Baral R; Driscoll AJ; Feikin DR; Fleming JA; Jit M; Kim S; Koltai M; Li Y; Li X; Nair H; Neuzil KM; Pecenka C; Sparrow E; Srikantiah P; Ortiz JR
    Vaccine; 2023 Nov; 41(48):7047-7059. PubMed ID: 37777450
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children.
    Nair H; Verma VR; Theodoratou E; Zgaga L; Huda T; Simões EA; Wright PF; Rudan I; Campbell H
    BMC Public Health; 2011 Apr; 11 Suppl 3(Suppl 3):S30. PubMed ID: 21501449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Estimating the economic burden of respiratory syncytial virus infections in infants in Vietnam: a cohort study.
    Do LAH; Vodicka E; Nguyen A; Le TNK; Nguyen TTH; Thai QT; Pham VQ; Pham TU; Nguyen TN; Mulholland K; Cao MT; Le NTN; Tran AT; Pecenka C
    BMC Infect Dis; 2023 Feb; 23(1):73. PubMed ID: 36747128
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.
    Kampmann B; Madhi SA; Munjal I; Simões EAF; Pahud BA; Llapur C; Baker J; Pérez Marc G; Radley D; Shittu E; Glanternik J; Snaggs H; Baber J; Zachariah P; Barnabas SL; Fausett M; Adam T; Perreras N; Van Houten MA; Kantele A; Huang LM; Bont LJ; Otsuki T; Vargas SL; Gullam J; Tapiero B; Stein RT; Polack FP; Zar HJ; Staerke NB; Duron Padilla M; Richmond PC; Koury K; Schneider K; Kalinina EV; Cooper D; Jansen KU; Anderson AS; Swanson KA; Gruber WC; Gurtman A;
    N Engl J Med; 2023 Apr; 388(16):1451-1464. PubMed ID: 37018474
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007-2012.
    Reeves RM; Hardelid P; Gilbert R; Warburton F; Ellis J; Pebody RG
    Influenza Other Respir Viruses; 2017 Mar; 11(2):122-129. PubMed ID: 28058797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand.
    Prasad N; Read JM; Jewell C; Waite B; Trenholme AA; Huang QS; Grant CC; Newbern EC; Hogan AB
    Vaccine; 2021 Jul; 39(31):4383-4390. PubMed ID: 34147296
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and epidemiologic features of respiratory syncytial virus.
    Hall CB; Simőes EA; Anderson LJ
    Curr Top Microbiol Immunol; 2013; 372():39-57. PubMed ID: 24362683
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential impact of a maternal vaccine for RSV: A mathematical modelling study.
    Hogan AB; Campbell PT; Blyth CC; Lim FJ; Fathima P; Davis S; Moore HC; Glass K
    Vaccine; 2017 Oct; 35(45):6172-6179. PubMed ID: 28967522
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting.
    Campbell PT; Geard N; Hogan AB
    BMC Med; 2020 Nov; 18(1):319. PubMed ID: 33176774
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A latent class analysis of factors influencing preferences for infant respiratory syncytial virus (RSV) preventives among pregnant people in the United States.
    Maculaitis MC; Hauber B; Beusterien KM; Will O; Kopenhafer L; Law AW; Vietri JT; Cappelleri JC; Coulter JR; Pugh S; Shea KM
    Hum Vaccin Immunother; 2024 Dec; 20(1):2358566. PubMed ID: 38847198
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective.
    Wittenauer R; Pecenka C; Baral R
    BMC Med; 2023 Mar; 21(1):121. PubMed ID: 37004038
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RSV vaccine use--the missing data.
    Drysdale SB; Sande CJ; Green CA; Pollard AJ
    Expert Rev Vaccines; 2016; 15(2):149-52. PubMed ID: 26636902
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness.
    Feikin DR; Karron RA; Saha SK; Sparrow E; Srikantiah P; Weinberger DM; Zar HJ
    Lancet Infect Dis; 2024 May; 24(5):e318-e327. PubMed ID: 38000374
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya.
    Nokes DJ; Okiro EA; Ngama M; Ochola R; White LJ; Scott PD; English M; Cane PA; Medley GF
    Clin Infect Dis; 2008 Jan; 46(1):50-7. PubMed ID: 18171213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.